Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of sunitinib in previously treated type B3 thymoma or thymic carcinoma
2016-003199-27Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in thymoma, thymic carcinoma (TC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Dec 2020; status: completed.
02
Drugs
sunitinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on 2016-003199-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003199-27.